Anthracycline
Top View
- Do Not Administer Doxorubicin Hcl in Combination with Trastuzumab
- Management of Cardiac Toxicity Induced by Chemotherapy
- Benzyladriamycin-14-Valerate with the C1-Regulatory Domain of Protein Kinase C: Structural Requirements, Isoform Specificity, and Correlation with Drug Cytotoxicity1
- Important Drug Information
- Anthracyclines
- Pediatric Cardio-Oncology: Development of Cancer Treatment-Related Cardiotoxicity and the Therapeutic Approach to Affected Patients Thomas D
- Facile Formation of a Crosslinked Adduct Between DNA And
- Review of Medicines for the Treatment of Common Tumours in Children
- NCCP Chemotherapy Regimen
- Tyrosine Kinase Inhibition to Improve Anthracycline-Based Chemotherapy Efficacy in T-Cell Lymphoma
- DNA Topoisomerase II-Mediated Interaction of Doxorubicin and Daunorubicin Congeners with DNA1
- Investigation of the Mechanism of the Reduction of Anthracycline-Induced Cardiotoxicity by Qishen Huanwu Capsule Based on Network Pharmacology
- Topoisomerase II Inhibitors
- Bruton's Tyrosine Kinase Inhibitors Ibrutinib and Acalabrutinib
- Anthracyclines and Heart Failure Douglas B
- Herceptin, INN-Trastuzumab
- Selection of Optimal Adjuvant Chemotherapy And
- DRUG NAME: Doxorubicin